NEW YORK, July 31, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Inotek Pharmaceuticals Corporation (NASDAQ: ITEK). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=ITEK
Highlights from our ITEK Report include:
- Appointment of Cadmus Collins Rich - On July 22, 2015, Inotek Pharmaceuticals Corporation announced appointment of Cadmus Collins Rich as Vice President of Medical Affairs and Clinical Development. The Company informed that most recently Dr. Rich had served as the Head of the Therapeutic Unit at Alcon for intraocular lenses and prior to that, he served as the Global Head of Pharmaceutical Clinical Trial Management at Alcon, leading a team of over 25 MDs and PhDs. In the words of Dr. Rudolf Baumgartner, Chief Medical Officer at Inotek, "Dr. Rich's clinical development experience will be important to us as we progress trabodenoson through clinical trials, and build our portfolio. We will also benefit from his years as a practicing ophthalmologist and the respect he has earned among a network of medical and scientific specialists focused on ophthalmology. We look forward to his contributions as we grow our company and advance trabodenoson towards an NDA."
- Selection of Richard N. Spivey to the Board - A day before, on July 21, 2015, Inotek Pharmaceuticals Corporation reported appointment of Richard N. Spivey, to the Company's Board of Directors. Commenting on the appointment, David P. Southwell, President and CEO stated that Richard N. Spivey has a distinguished background in drug development and regulatory affairs, spanning 30 years at leading pharmaceutical companies. He added that the Company is optimistic on benefiting from Richard's expert guidance, especially on regulatory and commercial strategy. The Company informed that Dr. Spivey served as Senior Vice President of Global Regulatory Affairs at Allergan, during the approval and launch of Ozurdex, for the treatment of diabetic macular edema and Botox, a novel treatment for spasticity, chronic migraine, overactive bladder, neurogenic bladder, and crow's feet lines. In addition, he provided ongoing oversight for development programs in glaucoma and retinal disease, including drug/device combination products.
- Appointment of Claudine Prowse - Additionally on July 20, 2015, the Company announced appointment of Claudine Prowse, as VP of Strategy and Investor Relations. According the Company, Claudine Prowse in her new role will directly report to David P. Southwell and will be responsible for defining corporate strategy to expand business opportunities, corporate communications and investor relations, and interfacing with key external business and investor constituents. Further, the Company informed that she has more than 15 years of experience in the biotechnology industry and has previously served as VP of Investor Relations at Biogen.
To find out how this influences our rating on Inotek Pharmaceuticals Corporation, read the full report in its entirety here: http://www.aciassociation.com/?c=ITEK
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.